Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients-Reference-Cited by-同舟云学术

Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients

Published:2018-03 Issue: Volume:88 Page:83-90
ISSN:0896-8411
Container-title:Journal of Autoimmunity
language:en
Short-container-title:Journal of Autoimmunity

Author:

Kalluri Sudhakar Reddy,Grummel Verena,Hracsko Zsuzsanna,Pongratz Viola,Pernpeintner Verena,Gasperi Christiane^ORCID,Buck Dorothea,Hemmer Bernhard

Funder

ABIRISK consortium

German Competence Network Multiple Sclerosis

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference26 articles.

1. Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: a systematic review and meta-analysis;Signori;Mult. Scler. Relat. Disord.,2016

2. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis;Polman;Lancet Neurol.,2010

3. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group;Neurology,1996

4. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS;Francis;Neurology,2005

5. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study;Kappos;Neurology,2005

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of IFNβ-1a versions with reduced immunogenicity and full in vitro biological activity for the treatment of multiple sclerosis;Clinical Immunology;2023-12

2. Therapeutic proteins immunogenicity: a peptide point of view;Exploration of Drug Science;2023-10-26

3. Staphylococcus aureus: a bacterial candidate for multiple sclerosis incidence and progression;REV RES MED MICROBIO;2022

4. Interleukin-31 and soluble CD40L: new candidate serum biomarkers that predict therapeutic response in multiple sclerosis;Neurological Sciences;2022-07-18

5. Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis;CNS Drugs;2022-05-19